Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
45.73
-0.62 (-1.34%)
At close: May 14, 2025, 4:00 PM
45.73
0.00 (0.00%)
After-hours: May 14, 2025, 4:33 PM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Disc Medicine stock ranges from a low of $57 to a high of $132. The average analyst price target of $93.89 forecasts a 105.31% increase in the stock price over the next year.
Price Target: $93.89 (+105.31%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Disc Medicine stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 6 | 6 | 6 | 7 | 7 | 6 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $112 → $120 | Buy | Maintains | $112 → $120 | +162.41% | May 12, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $99 → $132 | Buy | Maintains | $99 → $132 | +188.65% | Mar 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $85 | Buy | Initiates | $85 | +85.87% | Mar 7, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $73 → $75 | Buy | Maintains | $73 → $75 | +64.01% | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $90 → $94 | Strong Buy | Maintains | $90 → $94 | +105.55% | Jan 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 447.96M
Revenue Next Year
n/a
EPS This Year
-5.01
from -3.96
EPS Next Year
-5.03
from -5.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 57.8M | 195.3M | ||
| Avg | n/a | 30.0M | 116.7M | ||
| Low | n/a | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 549.9% | ||
| Avg | - | - | 288.5% | ||
| Low | - | - | -67.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.88 | -3.74 | -1.43 | ||
| Avg | -5.01 | -5.03 | -4.24 | ||
| Low | -5.82 | -7.55 | -8.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.